SCHEMBL2490181

SCHEMBL2490181

Clc1nc2c3ccccc3cnc2c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
GPR3 P46089 1/20 0.44
MAPT P10636 2/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 2/20 0.42
CYP3A4 P08684 1/20 0.42
APEX1 P27695 1/20 0.42
PMP22 Q01453 1/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.38
CCR1 P32246 1/20 0.38
CCR8 P51685 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CYP2A6 P11509 3/20 0.35
CYP1A2 P05177 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE4B Q07343 2/20 0.34
PDE4A P27815 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488607 0.83 KDM4E (0.58) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL19748987 0.79 KDM4E (0.60) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL2488933 0.77 CYP2A6 (0.44) KDM4EGPR3MAPTALDH1A1L3MBTL1
SCHEMBL28203658 0.74 CYP2A6 (0.50) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL16577928 0.74 TDP1 (0.50) MAPTLMNAMAPK1CYP3A4APEX1
SCHEMBL30929922 0.74 TDP1 (0.50) MAPTLMNAMAPK1CYP3A4APEX1
SCHEMBL29476068 0.74 ALDH1A1 (0.40) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL284801 0.74 ALDH1A1 (0.40) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL241747 0.74 HPRT1 (0.54) KDM4EGPR3MAPTLMNAMAPK1
SCHEMBL2487695 0.73 KDM4E (0.40) KDM4EGPR3MAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991546-B1 NOVEL DIBENZO[c,h][1,5]NAPHTHYRIDINES AND THEIR USE AS DNA PROBES INST CURIE (FR) 2011-10-26 EP disclosed
US-7728128-B2 Dibenzo[c,h][1,5]naphthyridines and their use as DNA probes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICATE (INSERM) (FR) 2010-06-01 US disclosed
US-20090246772-A1 NOVEL DIBENZO[c,h][1,5]NAPHTHYRIDINES AND THEIR USE AS DNA PROBES INSTITUT CURIE (FR) 2009-10-01 US disclosed
EP-1826210-A1 Novel dibenzo[c,h][1,5]naphthyridines and their use as DNA probes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2007-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090246772-A1 NOVEL DIBENZO[c,h][1,5]NAPHTHYRIDINES AND THEIR USE AS DNA PROBES DNA2, DDB1, H1-5 KDM4E 2562/4885GPR3 3651/4885MAPT 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.